



PRESS RELEASE

FOR IMMEDIATE RELEASE

AEGERA THERAPEUTICS ANNOUNCES THE APPOINTMENT OF A NEW CHAIRMAN AND DIRECTOR

MONTREAL, March 19, 2007 – Aegera Therapeutics Inc. is extremely pleased to announce the appointment of Mr. James M. Rae as Chairman of the Board and Ms. Trudie Resch as Board Director.

"Jim's vast business and development experience will be instrumental in guiding and helping Aegera meet its clinical and business objectives in the field of cancer and pain-related therapeutics", stated Dr. Michael Berendt, President and CEO of Aegera Therapeutics. "Furthermore, Jim's knowledge and network will be synergistic to that of our current Board members and I am looking forward to working closely with him to accelerate our company's growth objectives."

Mr. Rae has more than 40 years experience in the pharmaceutical industry. He has held multiple executive positions ranging from Marketing Manager to President and CEO at Searle Canada (1969-1988) and Cangene Corporation (1988 – 1996). Since 1996, as President of Remedis Consulting, he has provided strategic and hands-on M&A consulting for numerous biotechnology companies including Cytochroma, Resolution Pharma and Vaxis Therapeutics. Mr. Rae also serves as Chairman of Queen's Scientific Breakthrough Fund, as Executive Director of Elastin Specialties Inc., and holds Board seats on three other Canadian biotechnology companies.

Also joining Aegera's Board of Directors is Ms. Trudie Resch, a long-standing biotechnology investment professional. Ms. Resch, currently responsible for managing the life sciences investment team at Desjardins Venture Capital, has a long and successful track record in life sciences investments across North America. Prior to her position with Desjardins, Ms. Resch worked as a business consultant to the industry where she was involved in a number of successful M&A transactions and prior to that, held the position of Vice-President and Partner with CDP Capital Technology Ventures. Commenting on Ms. Resch's appointment, Dr. Michael Berendt said that "Trudie brings to Aegera's Board of Directors significant business and financial experience that will add to and complement the expertise and networks of our other board members."

Dr. Berendt concluded that "With the addition of Jim and Trudie, to our Board of Directors, I am very confident that we have a Board with the experience, networks and skill sets to help accelerate the growth and development of Aegera as we continue to aggressively manage the clinical advancement of our apoptosis-focused programs."

Aegera's Board consists of the following members:

- Mr. James M. Rae, President, Remedis Consulting
- Dr. Michael J. Berendt, President & CEO, Aegera Therapeutics Inc.
- Dr. Luc Marengère, Managing General Partner, VenGrowth Equity Partners
- Dr. Louisa Petropoulos, Principal, Multiple Capital
- Mr. Joseph Regan, Vice-President, GrowthWorks
- Ms. Trudie Resch, Consultant, Desjardins Venture Capital
- Mr. Lennie Ryer, Vice-President & CFO, ConjuChem Biotechnologies Inc.

About Aegera Therapeutics Inc.

Aegera Therapeutics Inc. ("Aegera") is a clinical stage company focused on developing drugs to control apoptosis to address major unmet medical needs. Our lead programs are in development to induce apoptosis to kill cancer cells and to prevent apoptosis to save injured neuronal cells. AEG35156, which targets the key anti-apoptotic protein XIAP, is currently in multiple human clinical trials for the treatment of solid tumors and leukemia. Aegera is also developing potent small molecule IAP inhibitors for the treatment of multiple cancers and developing novel oral small molecules for the treatment of neuropathic pain and neuropathies induced by diabetes or chemotherapy. For more information: www.aegera.com

- 30 -

For further information:

Aegera Therapeutics Inc.

Donald Olds

Chief Operating Officer & CFO

(514) 288-5532 *295

donald.olds@aegera.com